Skip to main content
Erschienen in: Community Mental Health Journal 3/2013

01.06.2013 | Original Paper

Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients

verfasst von: Simon Zhornitsky, Ginette Aubin, Joelle Desfossés, Élie Rizkallah, Tania Pampoulova, Olivier Lipp, Jean-Pierre Chiasson, Emmanuel Stip, Stéphane Potvin

Erschienen in: Community Mental Health Journal | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Community functioning is a broad term that encompasses various ‘real world’ measures of disability among schizophrenia patients. It includes outcomes such as independent living, social competence and behavioural problems—all of which are priorities for treatment among schizophrenia patients, mental health care providers, and family members. An important goal for rehabilitation programs is to identify predictors of community functioning which, in turn, could be used as targets for intervention. The present case–control study examined socio-demographic and substance use disorder (SUD) variables as well as psychiatric, extrapyramidal, and cognitive symptoms as predictors of community functioning in schizophrenia patients with (DD patients; n = 31) and without comorbid SUDs (SCZ patients; n = 31), and non-psychosis substance abusers (SUD patients; n = 39). Psychiatric and extrapyramidal symptoms were evaluated with the Positive and Negative Syndrome Scale, the Calgary Depression Scale for Schizophrenia and the Extrapyramidal Symptoms Rating Scale. Cognition was evaluated using the Cambridge Neuropsychological Test Automated Battery (speed of processing, explicit and working memory). In SCZ patients, community functioning was predicted by explicit memory performance. In DD patients, community functioning was predicted by substance abuse, depression and speed of processing. In SUD patients, community functioning was predicted by substance abuse, positive symptoms and education. Our results suggest that cognition should be among the top treatment priorities in SCZ patients, whereas the key treatment targets in DD patients should be substance abuse and depression. Future studies will need to replicate the current findings, using prospective research designs.
Literatur
Zurück zum Zitat Addington, D., Addington, J., Maticka-Tyndale, E., & Joyce, J. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6, 201–208.PubMedCrossRef Addington, D., Addington, J., Maticka-Tyndale, E., & Joyce, J. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6, 201–208.PubMedCrossRef
Zurück zum Zitat Aubin, G., Chapparo, C., Gélinas, I., Stip, E., & Rainville, C. (2009). Use of the perceive, recall, plan and perform system of task analysis for persons with schizophrenia: A preliminary study. Australian Occupation Therapy Journal, 56(3), 189–199.CrossRef Aubin, G., Chapparo, C., Gélinas, I., Stip, E., & Rainville, C. (2009). Use of the perceive, recall, plan and perform system of task analysis for persons with schizophrenia: A preliminary study. Australian Occupation Therapy Journal, 56(3), 189–199.CrossRef
Zurück zum Zitat Barker, S., Barron, N., McFarland, B. H., & Bigelow, D. A. (1994). A community ability scale for chronically mentally ill consumers: Part I. Reliability and validity. Community Mental Health Journal, 30(4), 363–383.PubMedCrossRef Barker, S., Barron, N., McFarland, B. H., & Bigelow, D. A. (1994). A community ability scale for chronically mentally ill consumers: Part I. Reliability and validity. Community Mental Health Journal, 30(4), 363–383.PubMedCrossRef
Zurück zum Zitat Bozikas, V. P., Kosmidis, M. H., Kafantari, A., Gamvrula, K., Vasiliadou, E., Petrikis, P., et al. (2006). Community dysfunction in schizophrenia: rate-limiting factors. Progress in Neuropsychopharmacology and Biological Psychiatry, 30(3), 463–470.CrossRef Bozikas, V. P., Kosmidis, M. H., Kafantari, A., Gamvrula, K., Vasiliadou, E., Petrikis, P., et al. (2006). Community dysfunction in schizophrenia: rate-limiting factors. Progress in Neuropsychopharmacology and Biological Psychiatry, 30(3), 463–470.CrossRef
Zurück zum Zitat Carey, K. B., Carey, M. P., & Simons, J. S. (2003). Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. Journal of Nervous and Mental Disease, 191, 300–308.PubMed Carey, K. B., Carey, M. P., & Simons, J. S. (2003). Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. Journal of Nervous and Mental Disease, 191, 300–308.PubMed
Zurück zum Zitat Chouinard, G., & Margolese, H. C. (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research, 76, 247–265.PubMedCrossRef Chouinard, G., & Margolese, H. C. (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research, 76, 247–265.PubMedCrossRef
Zurück zum Zitat Cooper, L., Liberman, D., Tucker, D., Nuechterlein, K. H., Tsuang, J., & Barnett, H. L. (1999). Neurocognitive deficits in the dually diagnosed with schizophrenia and cocaine abuse. Psychiatric Rehabilitation Skills, 3, 231–245.CrossRef Cooper, L., Liberman, D., Tucker, D., Nuechterlein, K. H., Tsuang, J., & Barnett, H. L. (1999). Neurocognitive deficits in the dually diagnosed with schizophrenia and cocaine abuse. Psychiatric Rehabilitation Skills, 3, 231–245.CrossRef
Zurück zum Zitat Drake, R. E., Osher, F. C., Noordsy, D. L., Hurlbut, S. C., Teague, G. B., & Beaudett, M. S. (1990). Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin, 16, 57–67.PubMedCrossRef Drake, R. E., Osher, F. C., Noordsy, D. L., Hurlbut, S. C., Teague, G. B., & Beaudett, M. S. (1990). Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin, 16, 57–67.PubMedCrossRef
Zurück zum Zitat Elliott, R., McKenna, P. J., Robbins, T. W., & Sahakian, B. I. (1998). Specific neuropsychological deficits in schizophrenic patients with preserved intellectual function. Cognitive Neuropsychiatry, 3, 45–70.CrossRef Elliott, R., McKenna, P. J., Robbins, T. W., & Sahakian, B. I. (1998). Specific neuropsychological deficits in schizophrenic patients with preserved intellectual function. Cognitive Neuropsychiatry, 3, 45–70.CrossRef
Zurück zum Zitat Fett, A. K., Viechtbauer, W., Dominguez, M. D., Penn, D. L., van Os, J., & Krabbendam, L. (2011). The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neuroscience and Biobehavioral Reviews, 35(3), 573–588.PubMedCrossRef Fett, A. K., Viechtbauer, W., Dominguez, M. D., Penn, D. L., van Os, J., & Krabbendam, L. (2011). The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neuroscience and Biobehavioral Reviews, 35(3), 573–588.PubMedCrossRef
Zurück zum Zitat Fioravanti, M., Carlone, O., Vitale, B., Cinti, M. E., & Clare, L. (2005). A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychology Review, 15(2), 73–95.PubMedCrossRef Fioravanti, M., Carlone, O., Vitale, B., Cinti, M. E., & Clare, L. (2005). A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychology Review, 15(2), 73–95.PubMedCrossRef
Zurück zum Zitat Fischer, E. P., Shumway, M., & Owen, R. R. (2002). Priorities of consumers, providers, and family members in the treatment of schizophrenia. Psychiatric Services, 53(6), 724–729.PubMedCrossRef Fischer, E. P., Shumway, M., & Owen, R. R. (2002). Priorities of consumers, providers, and family members in the treatment of schizophrenia. Psychiatric Services, 53(6), 724–729.PubMedCrossRef
Zurück zum Zitat Grant, J. E., Chamberlain, S. R., Schreiber, L., & Odlaug, B. L. (2012). Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Dependence, 121(1–2), 159–162.PubMedCrossRef Grant, J. E., Chamberlain, S. R., Schreiber, L., & Odlaug, B. L. (2012). Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Dependence, 121(1–2), 159–162.PubMedCrossRef
Zurück zum Zitat Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophrenia Bulletin, 26(1), 119–136.PubMedCrossRef Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophrenia Bulletin, 26(1), 119–136.PubMedCrossRef
Zurück zum Zitat Joyal, C. C., Hallé, P., Lapierre, D., & Hodgins, S. (2003). Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research, 63, 297–299.PubMedCrossRef Joyal, C. C., Hallé, P., Lapierre, D., & Hodgins, S. (2003). Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research, 63, 297–299.PubMedCrossRef
Zurück zum Zitat Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.PubMedCrossRef Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.PubMedCrossRef
Zurück zum Zitat Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin, 36(6), 1115–1130.PubMedCrossRef Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin, 36(6), 1115–1130.PubMedCrossRef
Zurück zum Zitat Krausz, M., Mass, R., Haasen, C., & Gross, J. (1996). Psychopathology in patients with schizophrenia and substance abuse: A comparative clinical study. Psychopathology, 29, 95–103.PubMedCrossRef Krausz, M., Mass, R., Haasen, C., & Gross, J. (1996). Psychopathology in patients with schizophrenia and substance abuse: A comparative clinical study. Psychopathology, 29, 95–103.PubMedCrossRef
Zurück zum Zitat Lapworth, K., Dawe, S., Davis, P., Kavanagh, D., Young, R., & Saunders, J. (2009). Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addictive Behaviors, 34(4), 380–385.PubMedCrossRef Lapworth, K., Dawe, S., Davis, P., Kavanagh, D., Young, R., & Saunders, J. (2009). Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addictive Behaviors, 34(4), 380–385.PubMedCrossRef
Zurück zum Zitat Levaux, M. N., Potvin, S., Sepehry, A. A., Sablier, J., Mendrek, A., & Stip, E. (2007). Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry, 22(2), 104–115.PubMedCrossRef Levaux, M. N., Potvin, S., Sepehry, A. A., Sablier, J., Mendrek, A., & Stip, E. (2007). Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry, 22(2), 104–115.PubMedCrossRef
Zurück zum Zitat Maat, A., Fouwels, A., & de Haan, L. (2008). Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacology Bulletin, 41(3), 5–10.PubMed Maat, A., Fouwels, A., & de Haan, L. (2008). Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacology Bulletin, 41(3), 5–10.PubMed
Zurück zum Zitat Mauri, M. C., Volonteri, L. S., Fiorentini, A., Pirola, R., & Bareggi, S. R. (2007). Two weeks’ quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: A naturalistic study with drug plasma levels. Expert Opinion on Pharmacotherapy, 8(14), 2207–2213.PubMedCrossRef Mauri, M. C., Volonteri, L. S., Fiorentini, A., Pirola, R., & Bareggi, S. R. (2007). Two weeks’ quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: A naturalistic study with drug plasma levels. Expert Opinion on Pharmacotherapy, 8(14), 2207–2213.PubMedCrossRef
Zurück zum Zitat Mazhari, S., Badcock, J. C., Waters, F. A., Dragović, M., Badcock, D. R., & Jablensky, A. (2010). Impaired spatial working memory maintenance in schizophrenia involves both spatial coordinates and spatial reference frames. Psychiatry Research, 179(3), 253–258.PubMedCrossRef Mazhari, S., Badcock, J. C., Waters, F. A., Dragović, M., Badcock, D. R., & Jablensky, A. (2010). Impaired spatial working memory maintenance in schizophrenia involves both spatial coordinates and spatial reference frames. Psychiatry Research, 179(3), 253–258.PubMedCrossRef
Zurück zum Zitat Mueser, K. T., Drake, R. E., & Wallach, M. A. (1998). Dual diagnosis: A review of etiological theories. Addictive Behaviors, 23(6), 717–734.PubMedCrossRef Mueser, K. T., Drake, R. E., & Wallach, M. A. (1998). Dual diagnosis: A review of etiological theories. Addictive Behaviors, 23(6), 717–734.PubMedCrossRef
Zurück zum Zitat Negrete, J. C. (2003). Clinical aspects of substance abuse in persons with schizophrenia. Canadian Journal of Psychiatry, 48(1), 14–21. Negrete, J. C. (2003). Clinical aspects of substance abuse in persons with schizophrenia. Canadian Journal of Psychiatry, 48(1), 14–21.
Zurück zum Zitat Palmer, B. W., Heaton, R. K., Paulsen, J. S., Kuck, J., Braff, D., Harris, M. J., et al. (1997). Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology, 11(3), 437–446.PubMedCrossRef Palmer, B. W., Heaton, R. K., Paulsen, J. S., Kuck, J., Braff, D., Harris, M. J., et al. (1997). Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology, 11(3), 437–446.PubMedCrossRef
Zurück zum Zitat Potvin, S., Briand, C., Prouteau, A., Bouchard, R. H., Lipp, O., Lalonde, P., et al. (2005). CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain and Cognition, 59, 38–42.PubMedCrossRef Potvin, S., Briand, C., Prouteau, A., Bouchard, R. H., Lipp, O., Lalonde, P., et al. (2005). CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain and Cognition, 59, 38–42.PubMedCrossRef
Zurück zum Zitat Potvin, S., Pampoulova, T., Mancini-Marië, A., Lipp, O., Bouchard, R. H., & Stip, E. (2006a). Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. Journal of Neurology Neurosurgery and Psychiatry, 77(6), 796–798.CrossRef Potvin, S., Pampoulova, T., Mancini-Marië, A., Lipp, O., Bouchard, R. H., & Stip, E. (2006a). Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. Journal of Neurology Neurosurgery and Psychiatry, 77(6), 796–798.CrossRef
Zurück zum Zitat Potvin, S., Stip, E., Lipp, O., Mancini-Marië, A., Élie, R., Roy, M. A., et al. (2006b). Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorder: An open-label trial. Current Medical Research and Opinion, 22(7), 1277–1285.PubMedCrossRef Potvin, S., Stip, E., Lipp, O., Mancini-Marië, A., Élie, R., Roy, M. A., et al. (2006b). Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorder: An open-label trial. Current Medical Research and Opinion, 22(7), 1277–1285.PubMedCrossRef
Zurück zum Zitat Potvin, S., Sepehry, A. A., Stip, E. (2007). Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Australian and New Zealand Journal of Psychiatry, 41(10), 792–799.PubMedCrossRef Potvin, S., Sepehry, A. A., Stip, E. (2007). Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Australian and New Zealand Journal of Psychiatry, 41(10), 792–799.PubMedCrossRef
Zurück zum Zitat Prouteau, A., & Doron, J. (2008). Cognitive predictors of the community functioning dimensions in schizophrenia: State of the art and future directions. Encephale, 34(4), 360–368.PubMedCrossRef Prouteau, A., & Doron, J. (2008). Cognitive predictors of the community functioning dimensions in schizophrenia: State of the art and future directions. Encephale, 34(4), 360–368.PubMedCrossRef
Zurück zum Zitat Prouteau, A., Verdoux, H., Briand, C., Lesage, A., Lalonde, P., Nicole, L., et al. (2004). The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Research, 129(2), 171–177.PubMedCrossRef Prouteau, A., Verdoux, H., Briand, C., Lesage, A., Lalonde, P., Nicole, L., et al. (2004). The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Research, 129(2), 171–177.PubMedCrossRef
Zurück zum Zitat Prouteau, A., Verdoux, H., Briand, C., Lesage, A., Lalonde, P., Nicole, L., et al. (2005). Cognitive predictors of psychosocial functioning outcome in schizophrenia: A follow-up study of subjects participating in a rehabilitation program. Schizophrenia Research, 77(2–3), 343–353.PubMedCrossRef Prouteau, A., Verdoux, H., Briand, C., Lesage, A., Lalonde, P., Nicole, L., et al. (2005). Cognitive predictors of psychosocial functioning outcome in schizophrenia: A follow-up study of subjects participating in a rehabilitation program. Schizophrenia Research, 77(2–3), 343–353.PubMedCrossRef
Zurück zum Zitat Rabany, L., Weiser, M., Werbeloff, N., & Levkovitz, Y. (2011). Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSS. Schizophrenia Research, 126(1–3), 226–230.PubMedCrossRef Rabany, L., Weiser, M., Werbeloff, N., & Levkovitz, Y. (2011). Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSS. Schizophrenia Research, 126(1–3), 226–230.PubMedCrossRef
Zurück zum Zitat Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264(19), 2511–2518.PubMedCrossRef Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264(19), 2511–2518.PubMedCrossRef
Zurück zum Zitat Revheim, N., & Medalia, A. (2004). Verbal memory, problem-solving skills and community status in schizophrenia. Schizophrenia Research, 68(2–3), 149–158.PubMedCrossRef Revheim, N., & Medalia, A. (2004). Verbal memory, problem-solving skills and community status in schizophrenia. Schizophrenia Research, 68(2–3), 149–158.PubMedCrossRef
Zurück zum Zitat Ritsner, M. S., Blumenkrantz, H., Dubinsky, T., & Dwolatzky, T. (2006). The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery. Schizophrenia Research, 82(1), 39–49.PubMedCrossRef Ritsner, M. S., Blumenkrantz, H., Dubinsky, T., & Dwolatzky, T. (2006). The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery. Schizophrenia Research, 82(1), 39–49.PubMedCrossRef
Zurück zum Zitat Saperstein, A. M., Fuller, R. L., Avila, M. T., Adami, H., McMahon, R. P., Thaker, G. K., et al. (2006). Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophrenia Bulletin, 32(3), 498–506.PubMedCrossRef Saperstein, A. M., Fuller, R. L., Avila, M. T., Adami, H., McMahon, R. P., Thaker, G. K., et al. (2006). Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophrenia Bulletin, 32(3), 498–506.PubMedCrossRef
Zurück zum Zitat Scheller-Gilkey, G., Thomas, S. M., Woolwine, B. J., & Miller, A. H. (2002). Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophrenia Bulletin, 28, 223–231.PubMedCrossRef Scheller-Gilkey, G., Thomas, S. M., Woolwine, B. J., & Miller, A. H. (2002). Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophrenia Bulletin, 28, 223–231.PubMedCrossRef
Zurück zum Zitat Schiffer, B., Müller, B. W., Scherbaum, N., Forsting, M., Wiltfang, J., Leygraf, N., et al. (2010). Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain, 133(10), 3093–3103.PubMedCrossRef Schiffer, B., Müller, B. W., Scherbaum, N., Forsting, M., Wiltfang, J., Leygraf, N., et al. (2010). Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain, 133(10), 3093–3103.PubMedCrossRef
Zurück zum Zitat Silver, H., Shlomo, N., Hiemke, C., Rao, M. L., Ritsner, M., & Modai, I. (2002). Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers. European Neuropsychopharmacology, 12(2), 141–144.PubMedCrossRef Silver, H., Shlomo, N., Hiemke, C., Rao, M. L., Ritsner, M., & Modai, I. (2002). Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers. European Neuropsychopharmacology, 12(2), 141–144.PubMedCrossRef
Zurück zum Zitat Stip, E., Corbière, M., Boulay, L. J., Lesage, A., Lecomte, T., Leclerc, C., et al. (2007). Intrusion errors in explicit memory: Their differential relationship with clinical and social outcome in chronic schizophrenia. Cognitive Neuropsychiatry, 12(2), 112–127.PubMedCrossRef Stip, E., Corbière, M., Boulay, L. J., Lesage, A., Lecomte, T., Leclerc, C., et al. (2007). Intrusion errors in explicit memory: Their differential relationship with clinical and social outcome in chronic schizophrenia. Cognitive Neuropsychiatry, 12(2), 112–127.PubMedCrossRef
Zurück zum Zitat Tsang, H. W., Leung, A. Y., Chung, R. C., Bell, M., & Cheung, W. M. (2010). Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Australian and New Zeeland Journal of Psychiatry, 44(6), 495–504. Tsang, H. W., Leung, A. Y., Chung, R. C., Bell, M., & Cheung, W. M. (2010). Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Australian and New Zeeland Journal of Psychiatry, 44(6), 495–504.
Zurück zum Zitat Velligan, D. I., Mahurin, R. K., Diamond, P. L., Hazleton, B. C., Eckert, S. L., & Miller, A. L. (1997). The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research, 25(1), 21–31.PubMedCrossRef Velligan, D. I., Mahurin, R. K., Diamond, P. L., Hazleton, B. C., Eckert, S. L., & Miller, A. L. (1997). The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research, 25(1), 21–31.PubMedCrossRef
Zurück zum Zitat Wobrock, T., Sittinger, H., Behrendt, B., D’Amelio, R., Falkai, P., & Caspari, D. (2007). Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 257(4), 203–210.PubMedCrossRef Wobrock, T., Sittinger, H., Behrendt, B., D’Amelio, R., Falkai, P., & Caspari, D. (2007). Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 257(4), 203–210.PubMedCrossRef
Zurück zum Zitat Zhornitsky, S., Stip, E., Pampoulova, T., Rizkallah, E., Lipp, O., Bentaleb, L. A., et al. (2010). Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders, 25(13), 2188–2194.PubMedCrossRef Zhornitsky, S., Stip, E., Pampoulova, T., Rizkallah, E., Lipp, O., Bentaleb, L. A., et al. (2010). Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders, 25(13), 2188–2194.PubMedCrossRef
Zurück zum Zitat Zhornitsky, S., Stip, E., Desfossés, J., Pampoulova, T., Rizkallah, E., Rompré, P. P., et al. (2011). Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: A 12-week, pilot, case-control trial with quetiapine. Frontiers in Psychiatry, 2, 22.PubMedCrossRef Zhornitsky, S., Stip, E., Desfossés, J., Pampoulova, T., Rizkallah, E., Rompré, P. P., et al. (2011). Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: A 12-week, pilot, case-control trial with quetiapine. Frontiers in Psychiatry, 2, 22.PubMedCrossRef
Metadaten
Titel
Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients
verfasst von
Simon Zhornitsky
Ginette Aubin
Joelle Desfossés
Élie Rizkallah
Tania Pampoulova
Olivier Lipp
Jean-Pierre Chiasson
Emmanuel Stip
Stéphane Potvin
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Community Mental Health Journal / Ausgabe 3/2013
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI
https://doi.org/10.1007/s10597-012-9525-y

Weitere Artikel der Ausgabe 3/2013

Community Mental Health Journal 3/2013 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.